Verastem, Inc. (VSTM) · Nov 19, 2026 · Exec change

Verastem CEO transition gets a routine two-month handoff deal

CEO transition — $40,000/month for November–December 2026

Verastem’s CEO transition filing formalizes Michael Bailey’s two-month consulting handoff before he takes over January 1, with no strategic change.

Verastem is moving from the early commercialization of AVMAPKI FAKZYNJA CO-PACK toward broader clinical development of VS-7375, its KRAS G12D program, with the company already positioning Michael Bailey’s January 1, 2027 appointment as the next leadership phase.

This filing formalizes the handoff rather than changing the succession plan. Bailey will advise the current CEO and board through December 31 on the CEO transition, then assume the top job January 1.

The new information is limited to interim compensation and mechanics. Verastem will pay Bailey $40,000 per month for November and December, with payment allowed in cash, equity, or equity-based awards; the agreement can also be terminated with 30 days’ notice.

Nothing here changes the business plan, leadership timing, or operating outlook. The CEO appointment and planned retirement of Daniel Paterson were already announced in October, while Bailey’s commercial and oncology background was part of the original succession rationale.

Bottom line: This is a continuity document, not a new strategic event. It confirms a managed two-month transition with modest disclosed compensation, leaving Verastem’s underlying commercial and pipeline story unchanged.

What to watch next

Bailey becomes CEO on January 1, 2027

Original filing on SEC EDGAR

More Verastem, Inc. news

Verastem CEO transition gets a routine two-month handoff deal | VSTM Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.